Posted on by Newsdesk

Allergan Aesthetics To Launch Three New State-of-the-Art Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training

PR Newswire

  • Allergan Medical Institute (AMI) Training Centers to offer most comprehensive, training programs accelerating providers’ consultative and clinical skills
  • Innovative curriculum will empower providers to deliver outcomes with excellence and support loyal patient relationships


IRVINE, Calif.
, Feb. 12, 2025 /PRNewswire/ — Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, today announced Allergan Medical Institute (AMI) will open three new state-of-the-art training centers in the U.S. expanding access to high-quality, tailored training to licensed aesthetics providers. AMI’s unique curriculum, designed to accelerate the science and art of aesthetics, paired with the company’s outstanding portfolio of products, empowers providers and business owners to deliver desired patient outcomes and experiences.

“The new AMI Training Centers are designed to help expand and elevate our existing best-in-class training programs,” said Glen Curran, Senior Vice President, U.S., Allergan Aesthetics. “The facilities will offer a range of courses for providers at every stage of learning helping them to safely and effectively deliver excellent outcomes and increase patient satisfaction.”

Since its first aesthetic approval for BOTOX® Cosmetic (onabotulinumtoxinA), Allergan Aesthetics has led the industry, ensuring excellence in training to empower aesthetic providers to deliver safe, natural-looking results for their patients. AMI is committed to elevating the science and art of aesthetics through high-impact educational programs to aesthetic providers that enable them to advance their capabilities. With the new U.S. centers, AMI Training Centers will operate in more than ten locations globally.

DRIVING INNOVATION IN TRAINING
The new AMI Training Centers, strategically built in key markets, will leverage top innovations in products, clinical education, techniques, and technologies to drive continued growth and progress across the aesthetic market. The offerings are focused on delivering safe and desirable patient outcomes and helping aesthetic practices to create lasting business success for themselves through patient acquisition and satisfaction.

The Centers will feature AMI faculty trainers offering engaging hands-on curriculum and an unparalleled learning experience for providers and business managers, regardless of where they are in their learning journey. The AMI Training Centers, presided over by AMI Medical Director Dr. Saami Khalifian, are designed to enhance the clinical techniques, complications management expertise, and business acumen of participants. Trainees will gain the tools, skills, and confidence needed to continue their journey as aesthetic professionals, while building a community of mentors and peers to help foster ongoing success.

“I’ve been actively involved in bringing these training centers to life—working closely to develop innovative solutions, refine ideas, and guide these concepts from vision to reality. It’s an honor to offer such a groundbreaking training experience to professionals nationwide,” said Dr. Saami Khalifian, Double Board-Certified Dermatologist and Medical Director AMI Training Centers. “Allergan Aesthetics leads the industry in medical education by continually investing in robust programs that set a new standard for excellence. These Centers exemplify that commitment in ways unlike anything providers have seen before. My hope is that every participant leaves feeling empowered, equipped, and inspired to reach their highest potential faster than they ever thought possible.”

CONTINUED EXCELLENCE IN EDUCATION
Developed in partnership between Allergan Aesthetics and expert healthcare professionals, programming is high-caliber and intended to advance scientific knowledge and technical skills in a variety of formats including hands-on training, roundtable forums, national symposia, live webcast events, exclusive resources, and a robust online learning program, AMI online.

In November 2024, Allergan Aesthetics launched AMI Business Education to the AMI online learning platform to provide free courses to practitioners with business operations education.

The first training center, AMI Orange County, located at Allergan Aesthetics Headquarters in Irvine, Calif. is scheduled to open in 2025. Additional locations in Atlanta and Austin to follow. To learn more about the training centers, please visit: trainingcenters.amionline.com.  

About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.AllerganAesthetics.com.

About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn,Facebook, Instagram, X (formerly Twitter), and YouTube.

About Allergan Medical Institute (AMI)
AMI is the training arm of Allergan Aesthetics, delivering on its commitment to excellence in aesthetics education. AMI empowers aesthetics providers and business owners with innovative training offerings across Allergan Aesthetics robust portfolio of products to maximize educational impact and elevate the standard of exemplary patient experiences. For more information visit https://us.allerganmedicalinstitute.com/us/en/splash-page.html.

About AMI Online
AMI Online is a comprehensive learning platform featuring in-depth education and training on the Allergan Aesthetics Portfolio of Products available on demand, 24/7. It is designed to provide an adaptable, personalized learning experience that helps injectors of all levels further their knowledge, refine their skills, and advance their expertise. AMI Online enables injectors and their staff to review injection techniques, test their knowledge, earn certificates, and stay up to date with upcoming educational events. Allergan Medical Institute® Faculty offer expert training through engaging, personalized content available to all AMI Online members for free.

BOTOX® Cosmetic (onabotulinumtoxinA) Indications and Important Safety Information

Indications

BOTOX® Cosmetic (onabotulinumtoxinA) is indicated in adult patients for the temporary improvement in the appearance of:
– Moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity
– Moderate to severe lateral canthal lines associated with orbicularis oculi activity
– Moderate to severe forehead lines associated with frontalis activity
– Moderate to severe platysma bands associated with platysma muscle activity

SAFETY CONSIDERATIONS


WARNING: DISTANT SPREAD OF TOXIN EFFECT

 


Postmarketing reports indicate that the effects of BOTOX® Cosmetic and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses and approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and spasticity and at lower doses.

CONTRAINDICATIONS
BOTOX® Cosmetic is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.

WARNINGS AND PRECAUTIONS
Seek immediate medical attention if respiratory, speech, or swallowing difficulties occur. The potency Units of BOTOX® Cosmetic are not equivalent to other preparations of botulinum toxin products. Potential serious adverse reactions have been reported after BOTOX® Cosmetic injections for unapproved uses. Concomitant neuromuscular disorder may exacerbate clinical effects of treatment. Use with caution in patients with compromised respiratory function.

DRUG INTERACTIONS
Patients receiving concomitant treatment of BOTOX® Cosmetic and aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like agents), or muscle relaxants, should be observed closely because the effect of BOTOX® Cosmetic may be potentiated.

USE IN SPECIFIC POPULATIONS
There are no studies or adequate data from postmarketing surveillance on the developmental risk associated with use of BOTOX® Cosmetic in pregnant women. 

Please see full
Prescribing Information
 including Boxed Warning and
Medication Guide
.

Forward-Looking Statements  
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie’s operations is set forth in Item 1A, “Risk Factors,” of AbbVie’s 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. 

U.S. Media:

Ember Garrett
Communications and Public Relations
[email protected]

Kate McShane

Corporate Communications

[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/allergan-aesthetics-to-launch-three-new-state-of-the-art-training-centers-in-the-us-expanding-access-to-high-quality-aesthetics-training-302374118.html

SOURCE AbbVie